Associate Professor Maija Kohonen-Corish
Senior Research Fellow; Group Leader, Cancer Research Program, Garvan Institute of Medical Research; Cancer Institute NSW Fellow; Conjoint Associate Professor, School of Medicine, College of Health and Science, University of Western Sydney; Conjoint Senior Lecturer, St Vincent’s Hospital Clinical School, The University of New South Wales; Visiting Scholar, University of Sydney
Email: m.corish 'at' garvan.org.au
Research Group: Colon and Lung Cancer
2005 MHGSA Specialist Accreditation in Molecular Genetics, Human Genetics Society of Australasia
1988 PhD in Human Genetics, Australian National University, Canberra
1983 MSc University of Helsinki, Finland
1982 BSc University of Helsinki, Finland
Mladenova D, Daniel JJ, Dahlstrom JE, Bean E, Gupta R, Pickford R, Currey N, Musgrove EA, Kohonen-Corish MR (2011). The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut 60: 350-360.
Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR (2011). Loss of Special AT-Rich Binding Protein 1 Expression is a Marker of Poor Survival in Lung Cancer. J Thorac Oncol 6: 1-11.
Pangon L, Sigglekow ND, Larance M, Al-Sohaily S, Mladenova DN, Selinger CI, Musgrove EA, Kohonen-Corish MR (2010). The "Mutated in Colorectal Cancer" Protein Is a Novel Target of the UV-Induced DNA Damage Checkpoint. Genes Cancer 1: 917-926.
Kohonen-Corish MR, Al-Aama JY, Auerbach AD, Axton M, Barash CI, Bernstein I, Beroud C, Burn J, Cunningham F, Cutting GR, den Dunnen JT, Greenblatt MS, Kaput J, Katz M, Lindblom A, Macrae F, Maglott D, Moslein G, Povey S, Ramesar R, Richards S, Seminara D, Sobrido MJ, Tavtigian S, Taylor G, Vihinen M, Winship I, Cotton RG (2010). How to catch all those mutations--the report of the third Human Variome Project Meeting, UNESCO Paris, May 2010. Hum Mutat 31: 1374-1381.
Kohonen-Corish MR, Sigglekow ND, Susanto J, Chapuis PH, Bokey EL, Dent OF, Chan C, Lin BP, Seng TJ, Laird PW, Young J, Leggett BA, Jass JR and Sutherland RL (2007). Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene 26: 4435-4441.
Seng TJ, Currey N, Cooper WA, Lee C-S, Chan C, Horvath L, Sutherland RL, Kennedy C, McCaughan B and Kohonen-Corish M (2008). DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 99: 375-382.
Ollila S, Sarantaus L, Kariola R, Chan P, Hampel H, Holinksi-Feder E, Macrae F, Kohonen-Corish M, Gerdes A-M, Peltomaki P, Mangold E, de la Chapelle A, Greenblatt M, Nystrom M. Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology 2006; 131:1408-1417.
Kohonen-Corish MRJ, Cooper WA, Saab J, Thompson JF, Trent RJA, Millward MJ. Promoter hypermethylation of the O6-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J Invest Dermatol 2006; 126:167-171.
Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, Dent OF, Dhillon VS, Trent RJ, Chapuis PH, Bokey EL. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005; 23(10):2318-24.
Raevaara TE, Siitonen M, Lohi H, Hampel H, Lynch E, Lonnqvist KE, Holonski-Feder E, Sutter C, McKinnon W, Duraisamy S, Gerdes A, Peltomaki P, Kohonen-Corish MRJ, Mangold E, Macrae F, M G, de la Chapelle A, Nystrom M. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 2005; 129(2):537-549.